137 related articles for article (PubMed ID: 11957800)
1. [Evaluation of side effects after intrabladder instillations of preparations in patients with superficial bladder carcinoma].
Kaczmarek P; Błaszczyk J; Kowalski J; Niemirowicz J
Pol Merkur Lekarski; 2002 Jan; 12(67):39-42. PubMed ID: 11957800
[TBL] [Abstract][Full Text] [Related]
2. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.
Ali-El-Dein B; Nabeeh A; Ismail EH; Ghoneim MA
J Urol; 1999 Aug; 162(2):339-42. PubMed ID: 10411034
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
4. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
5. [Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
Saint F; Irani J; Salomon L; Legrand P; Abbou CC; Chopin D
Prog Urol; 2001 Dec; 11(6):1242-50. PubMed ID: 11859659
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
7. Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects.
Andius P; Fehrling M; Holmäng S
BJU Int; 2005 Dec; 96(9):1290-3. PubMed ID: 16287447
[TBL] [Abstract][Full Text] [Related]
8. Complications of intravesical therapy for urothelial cancer of the bladder.
Koya MP; Simon MA; Soloway MS
J Urol; 2006 Jun; 175(6):2004-10. PubMed ID: 16697786
[TBL] [Abstract][Full Text] [Related]
9. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
[TBL] [Abstract][Full Text] [Related]
10. [Intravesical BCG-therapy: comparison of side effects of Connaught (Toronto) and Pasteur (Paris) strains].
Champetier D; Valignat C; Lopez JG; Ruffion A; Devonec M; Perrin P
Prog Urol; 2000 Sep; 10(4):542-7. PubMed ID: 11064894
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
13. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
15. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
Canda AE; Tuzel E; Mungan MU; Yorukoglu K; Kirkali Z
Eur Urol; 2004 Apr; 45(4):465-9; discussion 469-70. PubMed ID: 15041110
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence].
Wu ZB; Lin GB; Chen BJ; Wu ZM; Rong RM
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):507-9. PubMed ID: 16188156
[TBL] [Abstract][Full Text] [Related]
17. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin.
Bilen CY; Inci K; Erkan I; Ozen H
J Urol; 2003 May; 169(5):1702-5. PubMed ID: 12686812
[TBL] [Abstract][Full Text] [Related]
19. [Topical immunotherapy with BCG in the adjuvant treatment of superficial bladder tumors--15-year-experience].
Geavlete P; Georgescu D; Arabagiu I
Chirurgia (Bucur); 2000; 95(2):157-68. PubMed ID: 14768319
[TBL] [Abstract][Full Text] [Related]
20. Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
Kaneko T; Fujita K; Homma Y
Int J Urol; 2006 Mar; 13(3):294-5. PubMed ID: 16643629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
